Zoetis Inc. $ZTS Position Raised by Lansing Management LP

Key Points

• Lansing Management LP increased its holdings in Zoetis Inc. by 30.8% during the first quarter, making it the fund’s 8th largest position, valued at approximately $4.34 million.
• Zoetis reported earnings per share of $1.76, exceeding analyst expectations of $1.62, contributing to a 4.2% year-over-year revenue growth for the quarter.
• Multiple analysts have downgraded their ratings on Zoetis, with Leerink Partners cutting theirs to "market perform" and Piper Sandler setting a new price target at $215.00, indicating mixed outlooks in the market.

Lansing Management LP raised its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 30.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,331 shares of the company's stock after purchasing an additional 6,200 shares during the quarter. Zoetis makes up approximately 3.6% of Lansing Management LP's portfolio, making the stock its 8th largest holding. Lansing Management LP's holdings in Zoetis were worth $4,335,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Lindbrook Capital LLC lifted its holdings in Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock valued at $612,000 after purchasing an additional 65 shares during the last quarter. Quotient Wealth Partners LLC lifted its holdings in Zoetis by 2.3% during the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock valued at $521,000 after purchasing an additional 72 shares during the last quarter. Broadway Wealth Solutions Inc. lifted its holdings in shares of Zoetis by 4.4% in the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after buying an additional 73 shares in the last quarter. Menard Financial Group LLC lifted its holdings in shares of Zoetis by 3.8% in the first quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock worth $305,000 after buying an additional 75 shares in the last quarter. Finally, Moseley Investment Management Inc. lifted its holdings in shares of Zoetis by 1.4% in the first quarter. Moseley Investment Management Inc. now owns 5,719 shares of the company's stock worth $942,000 after buying an additional 77 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.18% of the stock is owned by insiders.

Zoetis Trading Up 1.1%

Shares of ZTS opened at $156.45 on Friday. The firm's 50 day simple moving average is $153.51 and its 200 day simple moving average is $158.02. The company has a market capitalization of $69.34 billion, a P/E ratio of 26.93, a P/E/G ratio of 2.48 and a beta of 0.88. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis's quarterly revenue was up 4.2% on a year-over-year basis. During the same period last year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ZTS shares. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler increased their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Finally, UBS Group lowered their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $202.43.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.